{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:11:24Z","timestamp":1778231484344,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12325-026-03528-0","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:19:24Z","timestamp":1773130764000},"page":"2054-2070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The PKD Daily: Development and Content Validation of a Hybrid Diary for Tracking Urinary Events in Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD)"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-2952","authenticated-orcid":false,"given":"Meaghan","family":"O\u2019Connor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8783-9877","authenticated-orcid":false,"given":"Lynne","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9968-7057","authenticated-orcid":false,"given":"Laura Tesler","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1567-3281","authenticated-orcid":false,"given":"Elizabeth","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2450-7693","authenticated-orcid":false,"given":"Michelle","family":"Carty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-7306","authenticated-orcid":false,"given":"Sasikiran","family":"Nunna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1034-9049","authenticated-orcid":false,"given":"Dorothee","family":"Oberdhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"3528_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ekir.2023.02.1073","volume":"8","author":"RD Perrone","year":"2023","unstructured":"Perrone RD, Oberdhan D, Ouyang J, et al. OVERTURE: a worldwide, prospective, observational study of disease characteristics in patients with ADPKD. Kidney Int Rep. 2023;8:989\u20131001. https:\/\/doi.org\/10.1016\/j.ekir.2023.02.1073.","journal-title":"Kidney Int Rep"},{"key":"3528_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ekir.2020.03.011","volume":"5","author":"RD Perrone","year":"2020","unstructured":"Perrone RD, Chapman AB, Oberdhan D, et al. The NOCTURNE randomized trial comparing 2 tolvaptan formulations. Kidney Int Rep. 2020;5:801\u201312. https:\/\/doi.org\/10.1016\/j.ekir.2020.03.011.","journal-title":"Kidney Int Rep"},{"key":"3528_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100415","volume":"4","author":"D Oberdhan","year":"2022","unstructured":"Oberdhan D, Schaefer F, Cole JC, Palsgrove AC, Dandurand A, Guay-Woodford L. Polycystic kidney disease-related disease burden in adolescents with autosomal dominant polycystic kidney disease: an international qualitative study. Kidney Med. 2022;4:100415. https:\/\/doi.org\/10.1016\/j.xkme.2022.100415.","journal-title":"Kidney Med"},{"key":"3528_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"R-U M\u00fcller","year":"2022","unstructured":"M\u00fcller R-U, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease\u00a0International. Nephrol Dial Transplant. 2022;37:825\u201339. https:\/\/doi.org\/10.1093\/ndt\/gfab312.","journal-title":"Nephrol Dial Transplant"},{"key":"3528_CR5","doi-asserted-by":"publisher","unstructured":"Lischetzke T. Daily diary methodology. Encyclopedia of quality of life and well-being research. Springer, Dordrecht; 2014. p. 1413\u20139. https:\/\/doi.org\/10.1007\/978-94-007-0753-5_657.","DOI":"10.1007\/978-94-007-0753-5_657"},{"key":"3528_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.clinpsy.3.022806.091415","volume":"4","author":"S Shiffman","year":"2008","unstructured":"Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1\u201332. https:\/\/doi.org\/10.1146\/annurev.clinpsy.3.022806.091415.","journal-title":"Annu Rev Clin Psychol"},{"key":"3528_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/iwcomp\/iwaa019","volume":"32","author":"K Doherty","year":"2020","unstructured":"Doherty K, Balaskas A, Doherty G. The design of ecological momentary assessment technologies. Interact Comput. 2020;32:257\u201378. https:\/\/doi.org\/10.1093\/iwcomp\/iwaa019.","journal-title":"Interact Comput"},{"key":"3528_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-025-02165-1","volume":"8","author":"FD Mowlem","year":"2025","unstructured":"Mowlem FD, Trudeau JJ, Platko JV, et al. Best practice recommendations and considerations for designing and electronically implementing event-driven diaries in clinical trials. NPJ Digit Med. 2025;8:745. https:\/\/doi.org\/10.1038\/s41746-025-02165-1.","journal-title":"NPJ Digit Med"},{"key":"3528_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2014.7","volume":"5","author":"P Marquis","year":"2014","unstructured":"Marquis P, Lasch KE, Delgado-Herrera L, et al. Qualitative development of a patient-reported outcome symptom measure in diarrhea-predominant irritable bowel syndrome. Clin Transl Gastroenterol. 2014;5:e59. https:\/\/doi.org\/10.1038\/ctg.2014.7.","journal-title":"Clin Transl Gastroenterol"},{"key":"3528_CR10","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1007\/s11136-016-1335-1","volume":"25","author":"K Rosa","year":"2016","unstructured":"Rosa K, Delgado-Herrera L, Zeiher B, et al. Psychometric assessment of the IBS-D daily symptom diary and symptom event log. Qual Life Res. 2016;25:3197\u2013208. https:\/\/doi.org\/10.1007\/s11136-016-1335-1.","journal-title":"Qual Life Res"},{"key":"3528_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2013establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument. Value Health. 2011;14:967\u201377. https:\/\/doi.org\/10.1016\/j.jval.2011.06.014.","journal-title":"Value Health"},{"key":"3528_CR12","unstructured":"US Food & Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed 1 Nov 2025."},{"key":"3528_CR13","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed 1 Nov 2025."},{"key":"3528_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/1609406917702983","volume":"16","author":"KKF Cheng","year":"2017","unstructured":"Cheng KKF, Clark AM. Qualitative methods and patient-reported outcomes: measures development and adaptation. Int J Qual Methods. 2017;16:1609406917702983. https:\/\/doi.org\/10.1177\/1609406917702983.","journal-title":"Int J Qual Methods"},{"key":"3528_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"key":"3528_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/14780887.2014.955224","volume":"12","author":"J Brooks","year":"2015","unstructured":"Brooks J, McCluskey S, Turley E, King N. The utility of template analysis in qualitative psychology research. Qual Res Psychol. 2015;12:202\u201322. https:\/\/doi.org\/10.1080\/14780887.2014.955224.","journal-title":"Qual Res Psychol"},{"key":"3528_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","volume":"71","author":"D Oberdhan","year":"2018","unstructured":"Oberdhan D, Cole JC, Krasa HB, et al. Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument. Am J Kidney Dis. 2018;71:225\u201335. https:\/\/doi.org\/10.1053\/j.ajkd.2017.08.020.","journal-title":"Am J Kidney Dis"},{"key":"3528_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4314\/ahs.v18i3.25","volume":"18","author":"FA Arogundade","year":"2018","unstructured":"Arogundade FA, Akinbodewa AA, Sanusi AA, Okunola O, Hassan MO, Akinsola A. Clinical presentation and outcome of autosomal dominant polycystic kidney disease in Nigeria. Afr Health Sci. 2018;18:671\u201380. https:\/\/doi.org\/10.4314\/ahs.v18i3.25.","journal-title":"Afr Health Sci"},{"key":"3528_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3949\/ccjm.81gr.14001","volume":"81","author":"WE Braun","year":"2014","unstructured":"Braun WE. Advances in autosomal dominant polycystic kidney disease-2014 and beyond. Cleve Clin J Med. 2014;81:545\u201356. https:\/\/doi.org\/10.3949\/ccjm.81gr.14001.","journal-title":"Cleve Clin J Med"},{"key":"3528_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/ndt\/gfu073","volume":"29","author":"NF Casteleijn","year":"2014","unstructured":"Casteleijn NF, Visser FW, Drenth JPH, et al. A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2014;29:142\u201353. https:\/\/doi.org\/10.1093\/ndt\/gfu073.","journal-title":"Nephrol Dial Transplant"},{"key":"3528_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ki.2015.143","volume":"88","author":"S Horie","year":"2015","unstructured":"Horie S. Will introduction of tolvaptan change clinical practice in autosomal dominant polycystic kidney disease? Kidney Int. 2015;88:14\u20136. https:\/\/doi.org\/10.1038\/ki.2015.143.","journal-title":"Kidney Int"},{"key":"3528_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1053\/j.ajkd.2019.12.003","volume":"76","author":"B Sautenet","year":"2020","unstructured":"Sautenet B, Cho Y, Gutman T, et al. Range and variability of outcomes reported in randomized trials conducted in patients with polycystic kidney disease: a systematic review. Am J Kidney Dis. 2020;76:213\u201323. https:\/\/doi.org\/10.1053\/j.ajkd.2019.12.003.","journal-title":"Am J Kidney Dis"},{"key":"3528_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/1319-2442.198163","volume":"28","author":"S Vikrant","year":"2017","unstructured":"Vikrant S, Parashar A. Autosomal dominant polycystic kidney disease: study of clinical characteristics in an Indian population. Saudi J Kidney Dis Transpl. 2017;28:115\u201324. https:\/\/doi.org\/10.4103\/1319-2442.198163.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"3528_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10157-016-1297-1","volume":"21","author":"NF Casteleijn","year":"2017","unstructured":"Casteleijn NF, Messchendorp AL, Bae KT, et al. Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients. Clin Exp Nephrol. 2017;21:375\u201382. https:\/\/doi.org\/10.1007\/s10157-016-1297-1.","journal-title":"Clin Exp Nephrol"},{"key":"3528_CR25","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ekir.2020.03.013","volume":"5","author":"RD Perrone","year":"2020","unstructured":"Perrone RD, Chapman AB, Oberdhan D, et al. A randomized trial of modified-release versus immediate-release tolvaptan in ADPKD. Kidney Int Rep. 2020;5:790\u2013800. https:\/\/doi.org\/10.1016\/j.ekir.2020.03.013.","journal-title":"Kidney Int Rep"},{"key":"3528_CR26","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/jcph.880","volume":"57","author":"SE Shoaf","year":"2017","unstructured":"Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS. Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase\u00a02 trials for dose selection in the pivotal phase\u00a03 trial. J Clin Pharmacol. 2017;57:906\u201317. https:\/\/doi.org\/10.1002\/jcph.880.","journal-title":"J Clin Pharmacol"},{"key":"3528_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1590\/S0101-28002011000200002","volume":"33","author":"BP de Barros","year":"2011","unstructured":"de Barros BP, Nishiura JL, Heilberg IP, Kirsztajn GM. Anxiety, depression, and quality of life in patients with familial glomerulonephritis or autosomal dominant polycystic kidney disease. J Bras Nefrol. 2011;33:120\u20138.","journal-title":"J Bras Nefrol"},{"key":"3528_CR28","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/apt.12413","volume":"38","author":"ES Dellon","year":"2013","unstructured":"Dellon ES, Irani A-M, Hill MR, Hirano I. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Aliment Pharmacol Ther. 2013;38:634\u201342. https:\/\/doi.org\/10.1111\/apt.12413.","journal-title":"Aliment Pharmacol Ther"},{"key":"3528_CR29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jval.2016.11.001","volume":"20","author":"SE Fehnel","year":"2017","unstructured":"Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ. Development of the diary for irritable bowel syndrome symptoms to assess treatment benefit in clinical trials: foundational qualitative research. Value Health. 2017;20:618\u201326. https:\/\/doi.org\/10.1016\/j.jval.2016.11.001.","journal-title":"Value Health"},{"key":"3528_CR30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/s13104-017-2814-3","volume":"10","author":"E Flood","year":"2017","unstructured":"Flood E, Silberg DG, Romero B, Beusterien K, Erder MH, Cuffari C. Development of the pediatric daily ulcerative colitis signs and symptoms scale (DUCS): qualitative research findings. BMC Res Notes. 2017;10:491. https:\/\/doi.org\/10.1186\/s13104-017-2814-3.","journal-title":"BMC Res Notes"},{"key":"3528_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jval.2016.01.007","volume":"19","author":"A Gater","year":"2016","unstructured":"Gater A, Nelsen L, Fleming S, et al. Assessing asthma symptoms in adolescents and adults: qualitative research supporting development of the Asthma Daily Symptom Diary. Value Health. 2016;19:440\u201350. https:\/\/doi.org\/10.1016\/j.jval.2016.01.007.","journal-title":"Value Health"},{"key":"3528_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0799-1","volume":"15","author":"A Hareendran","year":"2017","unstructured":"Hareendran A, Mannix S, Skalicky A, et al. Development and exploration of the content validity of a patient-reported outcome measure to evaluate the impact of migraine- the migraine physical function impact diary (MPFID). Health Qual Life Outcomes. 2017;15:224. https:\/\/doi.org\/10.1186\/s12955-017-0799-1.","journal-title":"Health Qual Life Outcomes"},{"key":"3528_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40271-017-0266-4","volume":"11","author":"BM Kamath","year":"2018","unstructured":"Kamath BM, Abetz-Webb L, Kennedy C, et al. Development of a novel tool to assess the impact of itching in pediatric cholestasis. Patient. 2018;11:69\u201382. https:\/\/doi.org\/10.1007\/s40271-017-0266-4.","journal-title":"Patient"},{"key":"3528_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jval.2017.08.3017","volume":"21","author":"L Kleinman","year":"2018","unstructured":"Kleinman L, Talbot GH, Hunsche E, Sch\u00fcler R, Nord CE. The CDI-DaySyms: content development of a new patient-reported outcome questionnaire for symptoms of Clostridium difficile infection. Value Health. 2018;21:441\u20138. https:\/\/doi.org\/10.1016\/j.jval.2017.08.3017.","journal-title":"Value Health"},{"key":"3528_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-019-1121-1","volume":"17","author":"RA Mesa","year":"2019","unstructured":"Mesa RA, Su Y, Woolfson A, et al. Development of a symptom assessment in patients with myelofibrosis: qualitative study findings. Health Qual Life Outcomes. 2019;17:61. https:\/\/doi.org\/10.1186\/s12955-019-1121-1.","journal-title":"Health Qual Life Outcomes"},{"key":"3528_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.anai.2020.07.027","volume":"126","author":"DM Turner-Bowker","year":"2021","unstructured":"Turner-Bowker DM, Jalbert JJ, Krohe M, et al. A novel patient-reported outcomes instrument assessing the side effects of peanut oral immunotherapy. Ann Allergy Asthma Immunol. 2021;126:61\u20138. https:\/\/doi.org\/10.1016\/j.anai.2020.07.027.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"3528_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-017-0819-1","volume":"16","author":"FE van Nooten","year":"2018","unstructured":"van Nooten FE, Cline J, Elash CA, Paty J, Reaney M. Development and content validation of a patient-reported endometriosis pain daily diary. Health Qual Life Outcomes. 2018;16:3. https:\/\/doi.org\/10.1186\/s12955-017-0819-1.","journal-title":"Health Qual Life Outcomes"},{"key":"3528_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0529-0","volume":"14","author":"I Wiklund","year":"2016","unstructured":"Wiklund I, Anatchkova M, Oko-Osi H, et al. Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health Qual Life Outcomes. 2016;14:131. https:\/\/doi.org\/10.1186\/s12955-016-0529-0.","journal-title":"Health Qual Life Outcomes"},{"key":"3528_CR39","doi-asserted-by":"publisher","DOI":"10.2196\/21475","volume":"22","author":"M Galve Villa","year":"2020","unstructured":"Galve Villa M, S Palsson T, Cid Royo A, R Bjarkam C, Boudreau SA. Digital pain mapping and tracking in patients with chronic pain: longitudinal study. J Med Internet Res. 2020;22:e21475. https:\/\/doi.org\/10.2196\/21475.","journal-title":"J Med Internet Res"},{"key":"3528_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cct.2017.12.014","volume":"66","author":"H Minami","year":"2018","unstructured":"Minami H, Brinkman HR, Nahvi S, et al. Rationale, design and pilot feasibility results of a smartphone-assisted, mindfulness-based intervention for smokers with mood disorders: project mSMART MIND. Contemp Clin Trials. 2018;66:36\u201344. https:\/\/doi.org\/10.1016\/j.cct.2017.12.014.","journal-title":"Contemp Clin Trials"},{"key":"3528_CR41","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/jdv.15872","volume":"34","author":"M Rijsbergen","year":"2020","unstructured":"Rijsbergen M, van der Niemeyer KT, Rijneveld R, et al. Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology. J Eur Acad Dermatol Venereol. 2020;34:633\u20139. https:\/\/doi.org\/10.1111\/jdv.15872.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03528-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03528-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03528-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:37:54Z","timestamp":1778229474000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03528-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3528"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03528-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"15 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dorothee Oberdhan and Sasikiran Nunna are employees of Otsuka Pharmaceutical Development and Commercialization, Inc. (Otsuka). Meaghan O\u2019Connor, Lynne Broderick, Laura Tesler Waldman, Elizabeth Costa, and Michelle Carty are\/were employees of IQVIA, Inc. which received funding from Otsuka to complete the research described in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was reviewed and approved by WCG IRB (IRB study number 1334669). All participants received a study information sheet with details about the study prior to being interviewed. Participants also provided verbal consent at the start of each interview.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}